Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evalua...
September 01 2016 - 6:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that a
poster detailing preliminary results from the Company’s Phase 1A
study in healthy volunteers evaluating oral non-covalent
BTK-inhibitor SNS-062 will be presented at the European School of
Haematology’s 2nd International Conference on New Concepts in
B-Cell Malignancies being held September 9-11, 2016, at the Estoril
Congress Centre in Estoril, Portugal.
The details for the poster presentation are as
follows:
Date & Time: Saturday,
September 10, 2016, from 6:50 p.m. to 8:20 p.m. Central European
Time
Poster Title: A Phase 1a Study to
Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of
the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in
Healthy Subjects: Preliminary Results
The poster will be available on the Sunesis website
following the presentation.
Conference Call and Webcast
InformationSunesis will host a conference call and slide
webcast on, Monday, September 12 at 8:00 a.m. Eastern
Time. The call can be accessed by dialing (844) 296-7720 (U.S.
and Canada) or (574) 900-1148 (international), and entering
passcode 70718677. To access the live audio webcast, or the
subsequent archived recording, visit the "Investors and Media -
Calendar of Events" section of the Sunesis website
at www.sunesis.com. The webcast will be recorded and available
for replay on the company's website for two weeks.
About SNS-062SNS-062 is a novel,
second-generation BTK inhibitor, a class of kinase inhibitors that
selectively inhibits the enzyme Bruton's tyrosine
kinase (BTK). This target mediates signaling through the
B-cell receptor, which is critical for adhesion, migration,
proliferation and survival of normal and malignant B-lineage
lymphoid cells. Unlike other drugs in its class, SNS-062 has a
distinct kinase selectivity profile and binds non-covalently to the
BTK enzyme, potentially providing an opportunity to address the
leading resistance mechanism, a mutation in the enzyme’s binding
site required for covalent binding. In preclinical studies, SNS-062
demonstrated potent activity against Cys-481S mutated B-cell
malignancies, and is currently being studied in healthy subjects in
a Phase 1A, randomized, double-blind, placebo-controlled
dose-ranging study to investigate the drug’s safety,
pharmacokinetics, and pharmacodynamics. With a successful study
outcome, SNS-062 is expected to proceed to a Phase 1B/2 study in
patients with B-cell malignancies around year end 2016.
About Sunesis
PharmaceuticalsSunesis is a biopharmaceutical company
focused on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic
cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people
with cancer. Currently, the company is focused on pursuing
regulatory approval in Europe for its lead product candidate,
vosaroxin, for the treatment of relapsed or refractory acute
myeloid leukemia in patients aged 60 and older, as well as
advancing its novel kinase-inhibitor pipeline, which includes its
proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024